The Claim
In obese non-diabetic adults receiving liraglutide 3.0 mg daily, the presence of nausea or vomiting does not hinder improvements in weight-related quality of life at 20 weeks, as quality of life scores (physical function, self-esteem, work) improved similarly in participants with and without gastrointestinal side effects.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Nausea and vomiting caused by liraglutide do not prevent improvements in weight-related quality of life in obese non-diabetic adults after 20 weeks. People who experience these side effects report the same gains in physical function, self-esteem, and work ability as those who do not.
See the scientific wording
In obese non-diabetic adults treated with liraglutide 3.0 mg, the occurrence of nausea or vomiting does not impair improvements in weight-related quality of life at 20 weeks: quality of life scores (physical function, self-esteem, work) improved similarly in participants with and without gastrointestinal side effects.
Liraglutide makes the brain tell the body to eat less, causing weight loss. That weight loss makes people feel better about their physical abilities, self-image, and work. Even if they feel nauseous, the weight loss still happens and still makes them feel better.
What the research says
1 studyThe study found that people taking liraglutide 3.0 mg who had nausea or vomiting still felt better about their physical abilities, self-image, and work performance just as much as those without side effects, so the side effects didn't ruin their quality of life.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.